The connection between PAR2 and GSK3β appears to play a critical role in gastrointestinal disorders (IBS, IBD, CRC) since both molecules were found overexpressed/overactivated in the pathological epithelium, and conversely their inhibition improves symptoms, tissue injury and therapy (10–13). This evidence concerns the gene GSK3B and irritable bowel syndrome.